

## Original Article

# A Fixed Nitrous Oxide and Oxygen Mixture for Analgesia in Children With Leukemia With Lumbar Puncture—induced Pain: A Randomized, Double-blind Controlled Trial



Qiang Liu, PhD, Xiao-Min Chai, MD, Jun-Jun Zhang, MD, Yi-Ling Wang, MD, Yu Wang, PhD, Lu-Lu Gao, PhD, Ya-Liang Dai, MD, Hai-Xiang Gao, MD, Ting-Ting Zhang, MD, Jian-Qiang Yu, MD, and Yu-Xiang Li, PhD  
*School of Nursing (Q.L., X.-M.C., J.-J.Z., Y.-L.W., L.-L.G., Y.-L.D., H.-X.G., T.-T.Z., Y.-X.L.), Ningxia Medical University, Yinchuan; Ningxia Key Laboratory of Cerebrocranial Diseases (Q.L.), Department of Anatomy, Histology and Embryology, School of Basic Medical Sciences, Ningxia Medical University, Yinchuan; Department of Nursing (Y.W.), Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing; and Department of Pharmacology (J.-Q.Y.), Pharmaceutical Institute of Ningxia Medical University, Yinchuan, China*

## Abstract

**Context.** Leukemia is the most common cancer in the childhood population. Lumbar puncture (LP) plays central role in the diagnosis and treatment process, but options for analgesia are limited.

**Objectives.** The present study aims to evaluate the efficacy of a fixed N<sub>2</sub>O/O<sub>2</sub> mixture to reduce pain in children with leukemia during LP as compared with placebo.

**Methods.** A double-blind, placebo-controlled, and randomized clinical trial involving children who needed LP for diagnosis or treatment was conducted in the pediatrics department of the General Hospital of Ningxia Medical University. Eligible patients were randomly assigned to inhale either a fixed N<sub>2</sub>O/O<sub>2</sub> mixture or O<sub>2</sub>. The primary endpoint was the maximal pain level felt by the patient during the procedure measured using a numerical rating scale (0–10).

**Results.** One-hundred fourteen consecutive patients were enrolled in this study and randomized. Pain scores during the procedure showed a significant decrease in N<sub>2</sub>O/O<sub>2</sub> mixture—treated patients to 1.05 ± 1.40 versus 8.00 ± 2.13 in controls (*P* < 0.01). No serious adverse effects were attributed to N<sub>2</sub>O/O<sub>2</sub> mixture inhalation. Analysis of the satisfaction of patients receiving N<sub>2</sub>O/O<sub>2</sub> mixture indicated that medical staff were satisfied with this treatment.

**Conclusions.** This study demonstrated that self-administered fixed N<sub>2</sub>O/O<sub>2</sub> is efficient to reduce pain related to LP in children with leukemia. *J Pain Symptom Manage* 2019;57:1043–1050. © 2019 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

## Key Words

Lumbar puncture, nitrous oxide, procedural pain, analgesia

## Background

Leukemia is the most common cancer in the childhood population,<sup>1</sup> accounting for more than one-third of the total number of cancer cases in many developed countries.<sup>2</sup> Over 70% of leukemia cases in

children involve acute leukemia.<sup>3,4</sup> Over the past decade, development of new therapy techniques has allowed the cure of pediatric acute leukemia.<sup>5</sup> The five-year survival rate of childhood acute leukemia has improved to over 80% in the U.S. and 70% in China.<sup>6,7</sup> However, increasing evidence shows that children and

Q. L. and X.-M. C. contributed equally to this work.

Trial registration: China Registry of Clinical Trials (ChiCTR-19R-16007989).

Address correspondence to: Yu-Xiang Li, PhD, Ningxia Medical University, 1160 Shengli Street, Yinchuan 750004, China. E-mail: [li\\_yuxiang@163.com](mailto:li_yuxiang@163.com)

Accepted for publication: February 26, 2019.

Table 1  
Patients' Inclusion and Exclusion Criteria

Inclusion Criteria	
	Patient aged five to 14 years
	Patient suffering from acute leukemia
	Patients need lumbar puncture
	Written informed consent for participation obtained before any study procedures
Exclusion Criteria	
	Patient with mental disorder and altered mental status
	Patient has difficulty to report pain
	Other N <sub>2</sub> O/O <sub>2</sub> contraindications, such as abdominal distension or suspected bowel obstruction, air embolism, and pneumothorax

their parents exhibit high levels of stress and uncertainty after diagnosis and subsequent treatment.<sup>8</sup> In China, treatment of pediatric acute leukemia has been estimated to require approximately 12 cycles of bone marrow aspiration and over 15 lumbar punctures (LPs) for intrathecal chemotherapy.<sup>8</sup> These repeated painful invasive procedures cause a common and distressing symptom among the pediatric population.

Unrelieved pediatric pain, as one of the most unbearable symptoms reported, significantly impairs patients' overall quality of life accompanied by negative physiological and psychological consequences.<sup>9</sup> Studies demonstrate that many children with acute leukemia undergoing LPs and bone marrow aspirations without optimal interventions report high levels of anxiety and pain.<sup>10</sup> As a consequence, the risk of failures increases in undertreated patients because of patient movement and noncooperation.

The World Health Organization three-step analgesia and clinical practice guidelines are widely used to control all kinds of pain.<sup>11</sup> Numerous studies focus on pharmacologic and nonpharmacologic measurements to control children procedural pain.<sup>12,13</sup> However, the lack of a specific reference standard for pediatric procedural pain management has led to poor management of LP pain in Northwest China.<sup>8</sup>

The use of a fixed self-administered inhaled N<sub>2</sub>O/O<sub>2</sub> mixture has been well studied in control burn dressing debridement pain, breakthrough cancer pain, trauma pain, and other medical conditions.<sup>14–18</sup> It has potent analgesic properties without causing loss of consciousness. The safety of self-administered N<sub>2</sub>O/O<sub>2</sub> mixture for pain management has also been demonstrated in previous studies.<sup>19,20</sup> In the present study, we aim to test the hypothesis that a fixed N<sub>2</sub>O/O<sub>2</sub> mixture can provide the same analgesic effect in controlling pain in patients with acute leukemia during their LP procedure.

## Methods

### Design

The present study was a randomized, double-blind, and placebo-controlled trial. Patients who met the described criteria were randomly assigned to receive

standard pain management plus N<sub>2</sub>O/O<sub>2</sub> mixture or standard pain management plus O<sub>2</sub>. This study was evaluated and approved by the General Hospital of Ningxia Medical University Ethics Service Committee (2015-130), and the trial was registered in the China Registry of Clinical Trials (ChiCTR-INR-16007989). Patients' consent was obtained in accordance with national regulations. This article was drafted in accordance with the Consolidated Standards of Reporting Trials (CONSORT) statement recommendations (Additional File 1).

### Study Participants

Patients aged five to 14 years and suffering from leukemia, needing LP, capable of reporting pain, and able to provide consent were recruited between February 2015 and July 2016 at the General Hospital of Ningxia Medical University. The specific inclusion and exclusion criteria are shown in Table 1.

### Treatments

Eligible patients received local injection of lidocaine for standard pain management. They also received a pre-prepared N<sub>2</sub>O/O<sub>2</sub> mixture in the treatment group or O<sub>2</sub> in the control group 5 minutes before the procedure started and lasted until the treatment finished. The N<sub>2</sub>O/O<sub>2</sub> mixture was self-administered by each patient through a self-demand mask with a one-way valve. In this way, overdose is nearly impossible because the patient's consciousness controlled their ability to inhale the gas.<sup>17</sup>

### Randomization, Allocation Concealment, and Binding

A total of 114 patients were assigned to the treatment or control groups by using a computer-generated randomization list. Thirty-eight patients received standard pain management plus O<sub>2</sub>, and 76 patients were allocated to standard pain treatment plus N<sub>2</sub>O/O<sub>2</sub> mixture. The randomization list was sealed and kept by an independent program director, who took charge of the gas distribution for each enrolled patient. Besides the program director, no other medical worker or data collector knew of the

intervention allocation. The project participants were blinded to the list.

### Sample Size Determination

The sample size was based on a previous randomized study showing analgesic superiority of nitrous oxide/oxygen mixture over placebo (O<sub>2</sub>) in adult patients undergoing LP. The patient material consisted of 33 patients in each group. To enhance power and provide substitution for possible dropouts, we decided to recruit 114 patients in treatment and control groups in a ratio of 2:1, 38 patients to control group and 76 patients to treatment group.

### Measurement

The patient's demographic data, including age, sex, and nationality, were recorded by the researchers. Our primary outcome was the numerical rating scale score measured 5 minutes before the procedure (T0), during the procedure (T1), and 5 minutes after the procedure (T2). The patients were instructed to rate their pain with a self-rating tool (ranging from 0 to 10, 0 = no pain, 10 = worst pain).<sup>21</sup> The secondary outcome was measured by focusing on the patients' blood pressure, heart rate, O<sub>2</sub> saturation, and satisfaction of the medical staff. Satisfaction was assessed by a five-point scale (5, very satisfied; 4, satisfied; 3, uncertain; 2, dissatisfied; and 1, very dissatisfied). Patients' anxiety during the procedure was assessed using a numerical rating scale (0–10, with 0 equal to the absence of anxiety and 10 equal to high anxiety). The measurement of anxiety occurred at the same time as pain assessment.

### Statistical Analysis

Statistical analysis was performed using SPSS 24.0 (SPSS Inc., IBM Company, Chicago, IL, USA) following the intention to treat principle that includes all interventions of the patients. We used the Kolmogorov-Smirnov test to determine whether the study data were normally distributed or not. Student's *t*-test was applied to determine differences in terms of age. We used the chi-squared test to determine gender differences between the two groups. Heart rate, blood pressure, O<sub>2</sub> saturation, and pain score were assessed using repeated-measures analysis of variance. The last observation carried forward method was applied in case of missing data.

Statistical significance was considered at  $P < 0.05$ .

### Results

From 1 February 2015 to 23 July 2016, among the 134 patients who were eligible and provided consent for participation, a subset of 114 patients were

randomly assigned to the two groups in this study and 109 patients were analyzed (Figure 1). Overall, 84 male and 30 female patients aged five to 14 years ( $9.55 \pm 3.41$  years) were included. Seventy-six patients were allocated to the N<sub>2</sub>O/O<sub>2</sub> group, and 38 patients were enrolled in the control group. No difference was observed between the two groups in terms of age and gender. Table 2 shows the patients' demographic and baseline characteristics. No differences with respect to pain score at T0 (no pain) was noted.

Patients pretreated with the N<sub>2</sub>O/O<sub>2</sub> mixture reported low pain intensity compared with the control group ( $1.05 \pm 1.40$  vs.  $8.00 \pm 2.13$ ,  $P < 0.01$ ) (Figure 2). In the N<sub>2</sub>O/O<sub>2</sub> mixture group, heart rates decreased from  $88.21 \pm 13.03$  (T0) to  $86.04 \pm 12.00$  (T1) and  $85.99 \pm 13.54$  (T2). In the O<sub>2</sub> group, heart rates increased from  $90.03 \pm 15.23$  (T0) to  $125.42 \pm 16.66$  (T1) and  $94.84 \pm 13.50$  (T2). The systolic and diastolic blood pressures of the O<sub>2</sub> group were higher than those of the N<sub>2</sub>O/O<sub>2</sub> mixture group at T1. The mean O<sub>2</sub> saturation levels at T0, T1, and T2 in the N<sub>2</sub>O/O<sub>2</sub> mixture group were  $98.37 \pm 0.88$ ,  $98.51 \pm 0.84$ , and  $98.66 \pm 0.70$ , respectively; by comparison, those of the control were  $98.50 \pm 0.78$ ,  $99.00 \pm 0.79$ , and  $98.97 \pm 0.56$ , respectively (Table 3). Analysis of the satisfaction of patients receiving N<sub>2</sub>O/O<sub>2</sub> mixture indicated that medical staff were satisfied with this treatment ( $Z = -11.96$ ,  $P < 0.01$ ). The anxiety level of patients receiving N<sub>2</sub>O/O<sub>2</sub> significantly decreased during the procedure ( $2.32 \pm 2.14$  vs.  $8.24 \pm 0.88$ ,  $P < 0.001$ ).

No serious adverse events related to N<sub>2</sub>O/O<sub>2</sub> mixture treatment were observed (Table 4). Among patients with mild side effects (such as nausea and vomiting), no treatment was usually required. All adverse effect symptoms disappeared 4 hours after completion of the procedure.

### Discussion

Multiple procedures, especially LP, are performed in children in pediatric department for the treatment of acute leukemia. Relieving pediatric pain and anxiety related to invasive procedures, such as LP aspirates for acute leukemia, is a shared goal. Several studies have shown that poor management of pain may place children at high risk for depression and anxiety.<sup>22,21,8</sup> Recent studies also show that many families report dissatisfaction with the light-sedation regimen when their children undergo painful procedures.<sup>23,22,24</sup> Therefore, controlling procedural pain in children is critical. A recent review offered numerous strategies to alleviate pain related to invasive procedures, and the literature indicates that both pharmacologic and nonpharmacologic interventions are effective.<sup>12</sup>



## CONSORT 2010 Flow Diagram




Fig. 1. CONSORT 2010 flow diagram.

Table 2  
Clinical Characteristics of Patients at T0 by Group

Variable	Group		P
	N <sub>2</sub> O/O <sub>2</sub> (n = 76)	O <sub>2</sub> (n = 38)	
Age (yrs) <sup>a</sup>	9.94 ± 3.30	9.11 ± 3.59	0.218
Males <sup>b</sup>	60 (80%)	24 (63.2%)	0.072
Heart rate (minute <sup>-1</sup> ) <sup>a</sup>	88.21 ± 13.03	90.03 ± 15.23	0.516
Systolic blood pressure (mm Hg) <sup>a</sup>	108.67 ± 13.65	109.03 ± 13.12	0.866
Diastolic blood pressure (mm Hg) <sup>a</sup>	73.54 ± 11.84	74.28 ± 7.50	0.580
SpO <sub>2</sub> (%) <sup>a</sup>	98.37 ± 0.877	98.50 ± 0.775	0.393
Number of prior LPs experienced by each patient before the study procedure			
0	25 (32.9%)	14 (36.8%)	0.804
1	19 (25.0%)	9 (23.7%)	
2	14 (18.4%)	8 (21.1%)	
3	12 (15.8%)	3 (7.9%)	
≥4	6 (7.9%)	4 (10.5%)	

Results are expressed as n (%) or means ± standard deviation.

<sup>a</sup>Based on *t*-test.

<sup>b</sup>Based on chi-square test.




Fig. 2. Pain score based on NRS for the case and control groups at T0, T1, and T2. NRS = numerical rating scale. \* $P < 0.01$  (based on  $t$ -test).

In the present study, we found that the pre-prepared  $N_2O/O_2$  mixture is an effective analgesic for management of LP pain in children when used in conjunction with local injection of lidocaine. LP is an extremely painful procedure for pediatric patients. This procedure is usually performed after local injection of anesthetic infiltration.<sup>25–27</sup> Studies demonstrate that using eutectic mixture of local anesthetics patch for at least 1 hour is efficient and avoids the first puncture of anesthetic injection.<sup>28</sup> A randomized control trial of patients with procedural pain who accepted buffered lidocaine solution or unbuffered preparations for LP biopsy procedures revealed that the former did not make LP biopsy less painful than the latter.<sup>29</sup> In a prospective trial, pretreatment with tramadol plus local injection of 2% lidocaine was reportedly associated with less pain intensity than placebo, thereby indicating that it could be a good local anesthetic for LP biopsy combined with local lidocaine injection.<sup>30</sup> Studies demonstrate that lidocaine administration usually causes mild local skin reactions, such as edema, pallor, or erythema, although other severe complications, such as methemoglobinemia, cardiotoxicity, and central nervous system toxicity, can also be encountered.<sup>31</sup>

Intravenous sedation, such as with lorazepam, midazolam, or diazepam, has been recommended for pain reduction during LP for this group of patients.<sup>32,33</sup> In this case, the child should be in the operating room and anesthetized by anesthesiologists to prevent complications. A prospective observational study of propofol/fentanyl in 202 patients aged six months to 14 years for short-term painful procedures in the pediatric oncology ward demonstrated that children benefit from general anesthesia by propofol and fentanyl, although 11.9% of them displayed complications, such as vomiting, agitation, and headache.<sup>34</sup> Moreover, this medication is much expensive, and some families cannot afford it.

Physiological variables, such as heart rate and blood pressure measurements, have been well studied for signs of acute pain in children.<sup>35–38</sup> Statistical analysis by repeated-measures one-way analysis

Table 3  
Heart Rate, Systolic Blood Pressure, Diastolic Blood Pressure, and  $O_2$  Saturation ( $SpO_2$ ) at T0, T1, and T2 in All Patients

Variable	Group	Main Effect of Group <sup>a</sup>			Group × Time Interaction <sup>a</sup>			Main Effect of time <sup>a</sup>		
		T0	T1	T2	T0	T1	T2	T0	T1	T2
Heart rate	$N_2O/O_2$ (n = 76)	88.21 ± 13.03	86.04 ± 12.00	85.99 ± 13.54	$P < 0.001$ (F = 78.173)	$P < 0.001$ (F = 65.303)	$P < 0.001$ (F = 55.921)			
	$O_2$ (n = 38)	90.03 ± 15.23	125.42 ± 16.66	94.84 ± 13.50						
Systolic blood pressure	$N_2O/O_2$ (n = 76)	108.67 ± 13.65	110.90 ± 13.61	104.65 ± 13.09	$P < 0.001$ (F = 77.702)	$P < 0.001$ (F = 64.974)	$P < 0.001$ (F = 55.637)			
	$O_2$ (n = 38)	109.03 ± 13.12	130.38 ± 18.70	121.09 ± 17.53						
Diastolic blood pressure	$N_2O/O_2$ (n = 76)	73.54 ± 11.84	73.26 ± 11.79	68.88 ± 9.95	$P = 0.043$ (F = 4.208)	$P = 0.001$ (F = 7.113)	$P < 0.001$ (F = 18.376)			
	$O_2$ (n = 38)	74.28 ± 7.50	82.03 ± 7.29	69.56 ± 12.02						
$O_2$ saturation	$N_2O/O_2$ (n = 76)	98.37 ± 0.877	98.51 ± 0.841	98.66 ± 0.703	$P = 0.002$ (F = 9.829)	$P = 0.252$ (F = 1.385)	$P = 0.001$ (F = 7.384)			
	$O_2$ (n = 38)	98.50 ± 0.775	99.00 ± 0.793	98.97 ± 0.560						

Results are presented as mean ± standard deviation and median (interquartile range).  
<sup>a</sup>Determined using repeated-measures analysis of variance (ANOVA). Significance set at  $P < 0.05$ .

**Table 4**  
**Adverse Events Over the Entire Course of Intervention by Group**

Group	N <sub>2</sub> O/O <sub>2</sub> (n = 76)	O <sub>2</sub> (n = 38)
Nausea	7 (9.2%)	0 (0%)
Somnolence	2 (2.6%)	0 (0%)
Dizziness	3 (3.95%)	1 (2.6%)
Total <sup>a</sup>	12 (15.79%)	1 (2.6%)

Results are expressed as n (%).

<sup>a</sup>Based on chi-squared test.  $P < 0.001$ .

of variance showed significant differences between the two groups in terms of heart rate and blood pressure. In the present study, the heart rate and blood pressure in the N<sub>2</sub>O/O<sub>2</sub> mixture group significantly decreased during the procedure compared with those in the control group ( $P < 0.01$ ). This result indirectly indicates decreased pain in the N<sub>2</sub>O/O<sub>2</sub> treatment group.

N<sub>2</sub>O, first used in anesthesia in 1772,<sup>39</sup> has been extensively studied in various procedures and areas, such as dental care, pulmonary endoscopy, venous cannulation, clip removal, fractures, and minor procedures (burn dressing and abscess drainage) because of its pain relief properties.<sup>20</sup> N<sub>2</sub>O/O<sub>2</sub> mixture is suitable for use as an analgesic in various procedures because of its analgesic properties, safety profile, rapid reversal, and self-administration by patients.<sup>40,41</sup> A randomized, double-blinded trial compared 50% N<sub>2</sub>O/O<sub>2</sub> inhalation with medical air inhalation to treat moderate-to-severe acute pain. The median pain scores at 15 minutes were 2 (interquartile range 1–4) in the study group versus 5 (interquartile range 3–6) in the control group ( $P < 0.05$ ).<sup>42</sup> Another randomized double-blinded study that compared a 50:50 ratio of N<sub>2</sub>O:O<sub>2</sub> with 50:50 N<sub>2</sub>:O<sub>2</sub> (placebo) for cutaneous, muscle, and bone/joint procedure-related pain in 100 patients aged one to 18 years found that pain scores were lower in the 50:50 N<sub>2</sub>O:O<sub>2</sub> group than in the placebo group and with rare minor side effects.<sup>43</sup> The effect size in our study is notably higher than that in the adult population possibly because children are sensitive to N<sub>2</sub>O than adults. In the present study, the patients also showed rare and minor adverse effects. Overall, N<sub>2</sub>O, as one of the earliest analgesics, is a safe and effective analgesic for procedural pain control in children.

### Limitations

The limitations of the present study include the recruitment of young patients in a single department. The study findings should be confirmed in different ages of patients, such as older patients, to determine true analgesia effects, adverse drug events, and the satisfaction of both health workers and patients. Another potential limitation is that we did not perform blinding evaluation. Large-sample studies should be implemented to test the analgesic effect

of N<sub>2</sub>O/O<sub>2</sub> mixture in multicenter randomized controlled trials.

### Conclusion

This study aims to demonstrate the efficacy, feasibility, and medical staff satisfaction of N<sub>2</sub>O/O<sub>2</sub> mixture plus local anesthesia of lidocaine to treat LP-related pain. We can conclude that N<sub>2</sub>O/O<sub>2</sub> provides significant pain relief to children with a low incidence of side effects during procedural pain. Health care providers in low-resource settings should consider inhalation of N<sub>2</sub>O/O<sub>2</sub> mixture as an effective approach to alleviate procedural pain in children.

### Disclosures and Acknowledgments

The invaluable contributions of the patients and staff of Ningxia Medical University, General Hospital of Ningxia Medical University, are gratefully acknowledged.

The study was supported by the Science and Technology Department of Ningxia (Project No.: 2018CMG03005).

The authors have no conflicts of interests to declare.

### Supplementary Data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jpainsymman.2019.02.029>.

### References

- Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. *JAMA* 1995;274:1870–1873.
- Stiller C. Epidemiology and genetics of childhood cancer. *Oncogene* 2004;23:6429–6444.
- Darling SJ, Luca C De, Anderson V, et al. White Matter Microstructure and Information Processing at the completion of chemotherapy-only treatment for pediatric acute lymphoblastic leukemia. *Dev Neuropsychol* [internet] Routledge 2018;00:1–18 <https://doi.org/10.1080/87565641.2018.1473401>.
- Mulatsih S, Dwiprahasto I. Implementation of medication safety practice in childhood acute lymphoblastic leukemia treatment. *Asian Pac J Cancer Prev* 2018;19:1251–1257.
- O'Donnell MR, Tallman MS, Abboud CN, et al. Acute myeloid leukemia, version 3.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2017;15:926–957.
- Ward E, Desantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. *CA Cancer J Clin* 2014;64:83–103.
- Zheng R, Peng X, Zeng H, et al. Incidence, mortality and survival of childhood cancer in China during 2000–2010 period: a population-based study. *Cancer Lett* 2015;363:176–180.
- Wang Y, Liu Q, Yu J, et al. Perceptions of parents and paediatricians on pain induced by bone marrow aspiration

and lumbar puncture among children with acute leukaemia: a qualitative study in China. *BMJ* 2017;1–10.

9. Lee GY, Yamada J, Kyololo O, Shorkey A, Stevens B. Pediatric clinical practice guidelines for acute procedural pain: a systematic review. *Pediatrics* 2014;133:500–515.

10. Kars MC, Duijnste MSH, Pool A, van Delden JJM, Grypdonck MHF. Being there: parenting the child with acute lymphoblastic leukaemia. *J Clin Nurs* 2008;17:1553–1562.

11. Ventafridda V, Saita L, Ripamonti C, De Conno F. WHO guidelines for the use of analgesics in cancer pain. *Int J Tissue React Switzerland* 1985;7:93–96.

12. Hjortholm N, Jaddini E. Strategies of pain reduction during the bone marrow biopsy. *Ann Hematol* 2013;145–149.

13. Zahid MF. Methods of reducing pain during bone marrow biopsy: a narrative review. *Ann Palliat Med* 2015;4:184–193.

14. Gao L-L, Yang L-S, Zhang J-J, et al. A fixed nitrous oxide/oxygen mixture as an analgesic for trauma patients in emergency department: study protocol for a randomized, controlled trial. *Trials* 2018;19:527.

15. Li Y-X, Han W-J, Tang H-T, et al. Nitrous oxide-oxygen mixture during burn wound dressing: A double-blind randomized controlled study. *CNS Neurosci Ther England* 2013;278–279.

16. Liu Q, Gao L-L, Dai Y-L, et al. Nitrous oxide/oxygen mixture for analgesia in adult cancer patients with breakthrough pain: a randomized, double-blind controlled trial. *Eur J Pain* 2018;22:492–500.

17. Liu Q, Wang Y, Luo X-J, et al. A fixed inhaled nitrous oxide/oxygen mixture as an analgesic for adult cancer patients with breakthrough pain: study protocol for a randomized controlled trial. *Trials* 2017;18:13.

18. Meskine N, Vullierme M-P, Zappa M, d'Assignies G, Sibert A, Vilgrain V. Evaluation of analgesic effect of equimolar mixture of oxygen and nitrous oxide inhalation during percutaneous biopsy of focal liver lesions: a double-blind randomized study. *Acad Radiol* 2011;18:816–821.

19. Aboumarzouk OM, Agarwal T, Syed Nong Chek SAH, Milewski PJ, Nelson RL. Nitrous oxide for colonoscopy. *Cochrane Database Syst Rev* 2011;10:CD008506.

20. Zafirova Z, Sheehan C, Hosseinian L. Update on nitrous oxide and its use in anesthesia practice. *Best Pract Res Clin Anaesthesiol* 2018;32:113–123.

21. Tsze DS, von Baeyer CL, Pahalyants V, Dayan PS. Validity and reliability of the verbal numerical rating scale for children aged 4 to 17 years with acute pain. *Ann Emerg Med* 2018;71:691–702.e3.

22. Kircher J, Drendel AL, Newton AS, Dulai S, Vandermeer B, Ali S. Pediatric musculoskeletal pain in the emergency department: a medical record review of practice variation. *CJEM* 2014;16:449–457.

23. Alexander J, Manno M. Underuse of analgesia in very young pediatric patients with isolated painful injuries. *Ann Emerg Med* 2003;41:617–622.

24. O'Donnell J, Ferguson LP, Beattie TF. Use of analgesia in a paediatric accident and emergency department following limb trauma. *Eur J Emerg Med* 2002;9:5–8.

25. Baek IC, Choi SY, Suh J, Kim SH. The influence of local anesthesia depth on procedural pain during fluoroscopically-guided lumbar transforaminal epidural injections: a randomized clinical trial. *Am J Phys Med Rehabil* 2019;98:253–257.

26. Firdaus R, Sukmono B, Melati AC, Marzaini BD. Comparison between vapocoolant spray and eutectic mixture of local anesthetics cream in reducing pain during spinal injections. *Anesthesiol Res Pract* 2018;5050273. 2018.

27. Hameed NN, Sargod SS, Bhat SS, Hegde SK, Bava MM. Effectiveness of precooling the injection site using tetrafluoroethane on pain perception in children. *J Indian Soc Pedod Prev Dent* 2018;36:296–300.

28. Koscielniak-Nielsen Z, Hesselbjerg L, Brushoj J, Jensen MB, Pedersen HS. EMLA patch for spinal puncture. A comparison of EMLA patch with lignocaine infiltration and placebo patch. *Anaesthesia* 1998;53:1218–1222.

29. Ruegg TA, Curran CR, Lamb T. Use of buffered lidocaine in bone marrow biopsies: a randomized, controlled trial. *Oncol Nurs Forum* 2009;36:52–60.

30. Vanhelleputte P, Nijs K, Delforge M, Evers G, Vanderschueren S. Pain during bone marrow aspiration: prevalence and prevention. *J Pain Symptom Manage* 2003;26:860–866.

31. Tran AN, Koo JY. Risk of systemic toxicity with topical lidocaine/prilocaine: a review. *J Drugs Dermatol* 2014;13:1118–1122.

32. Chakupurakal G, Delgado J, Nikolousis E, et al. Midazolam in conjunction with local anaesthesia is superior to Entonox in providing pain relief during bone marrow aspirate and trephine biopsy. *J Clin Pathol* 2008;61:1051–1054.

33. Friedman AG, Mulhern RK, Fairclough D, et al. Midazolam premedication for pediatric bone marrow aspiration and lumbar puncture. *Med Pediatr Oncol* 1991;19:499–504.

34. Burkle CM, Harrison BA, Koenig LF, Decker PA, Warner DO, Gastineau DA. Morbidity and mortality of deep sedation in outpatient bone marrow biopsy. *Am J Hematol* 2004;77:250–256.

35. Koenig J, Jarczok MN, Ellis RJ, Hillecke TK, Thayer JF. Heart rate variability and experimentally induced pain in healthy adults: a systematic review. *Eur J Pain* 2014;18:301–314.

36. Meschi M, Regolisti G, Detrenis S, Bianchi L. The relationship between blood pressure and pain. *J Clin Hypertens (Greenwich)* 2013;15:600–605.

37. Sesay M, Robin G, Tazuin-Fin P, et al. Responses of heart rate variability to acute pain after minor spinal surgery: optimal thresholds and correlation with the numeric rating scale. *J Neurosurg Anesthesiol* 2015;27:148–154.

38. Tejman-Yarden S, Levi O, Beizerov A, et al. Heart rate analysis by sparse representation for acute pain detection. *Med Biol Eng Comput* 2016;54:595–606.

39. Knuf K, Maani CV. Nitrous oxide. Treasure Island (FL): StatPearls, 2018.

40. Martin HA, Noble M, Wodo N. The benefits of introducing the Use of nitrous oxide in the pediatric emergency department for painful procedures. *J Emerg Nurs* 2018;44:331–335.

41. Pedersen RS, Bayat A, Steen NP, Jacobsson M-LB. Nitrous oxide provides safe and effective analgesia for minor paediatric procedures—a systematic review. *Dan Med J Denmark* 2013;60:A4627.
42. Ducasse J-L, Siksik G, Durand-Bechu M, et al. Nitrous oxide for early analgesia in the emergency setting: a randomized, double-blind multicenter prehospital trial. *Acad Emerg Med* 2013;20:178–184.
43. Reinoso-Barbero F, Pascual-Pascual SI, de Lucas R, et al. Equimolar nitrous oxide/oxygen versus placebo for procedural pain in children: a randomized trial. *Pediatrics* 2011; 127:e1464–e1470.